733 related articles for article (PubMed ID: 18308107)
1. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
2. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
J Urol; 2006 May; 175(5):1634-9; discussion 1639-40. PubMed ID: 16600718
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
4. Clinical study of bladder cancer: Proteinuria as a predictor of recurrence and efficacy of intravesical bacille Calmette-Guerin therapy.
Satoh A; Hanawa Y; Nakamura S
Int J Urol; 2004 Jul; 11(7):476-82. PubMed ID: 15242355
[TBL] [Abstract][Full Text] [Related]
5. Treatment of BCG failures with intravesical BCG/Interferon: the University of Montreal experience.
Karakiewicz PI; Benayoun S; Lewinshtein DJ; Chun FK; Shahrour K; Perrotte P
Can J Urol; 2006 Aug; 13(4):3189-94. PubMed ID: 16952327
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
Pan CW; Shen ZJ; Ding GQ
J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
[TBL] [Abstract][Full Text] [Related]
7. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
8. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
9. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
Boorjian SA; Zhu F; Herr HW
BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
[TBL] [Abstract][Full Text] [Related]
10. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
O'Donnell MA; Krohn J; DeWolf WC
J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
[TBL] [Abstract][Full Text] [Related]
11. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
12. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
Han RF; Pan JG
Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
14. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.
Cai T; Nesi G; Dal Canto M; Tinacci G; Mondaini N; Piazzini M; Geppetti P; Bartoletti R
J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058
[TBL] [Abstract][Full Text] [Related]
16. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
Punnen SP; Chin JL; Jewett MA
Can J Urol; 2003 Apr; 10(2):1790-5. PubMed ID: 12773228
[TBL] [Abstract][Full Text] [Related]
17. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
18. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
20. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y;
Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]